Nanostim Meets Goals In Short Trial, But Big Questions Remain For Leadless Pacemakers
This article was originally published in The Gray Sheet
Executive Summary
St. Jude's leadless pacemaker met its endpoints in the 526-patient LEADLESS II trial, but the 6.7 percent adverse event rate triggered questions at the European Society of Cardiology Congress, and investigators underscored the current limitations of leadless devices compared to conventional pacemakers.